Dendritic polylysine co-delivery of paclitaxel and siAXL enhances the sensitivity of triple-negative breast cancer chemotherapy

被引:1
|
作者
Wan, Xiaofeng [1 ]
Chen, Chuanrong [2 ]
Zhan, Jianmin [1 ]
Ye, Shuke [1 ]
Li, Runsheng [1 ]
Shen, Ming [1 ]
机构
[1] Shanghai Inst Biomed & Pharmaceut Technol, Natl Hlth Commiss NHC, Key Lab Reprod Regulat, Shanghai, Peoples R China
[2] Yijishan Hosp, Dept Oncol, Wannan Med Coll, Wuhu, Peoples R China
基金
中国国家自然科学基金;
关键词
dendritic polylysine; siRNA delivery; tumor microenvironment sensitivity; drug resistance; triple-negative breast cancer; EXTRACELLULAR PH; RESISTANCE; AXL; SYSTEM; TUMORS;
D O I
10.3389/fbioe.2024.1415191
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background: Drug resistance is common in triple-negative breast cancer (TNBC) therapy. To identify a method to overcome chemotherapy resistance in TNBC cells, an siRNA targeting the AXL gene (siAXL), which can overcome drug resistance, was used in this study. A nanodelivery system was constructed to co-deliver siAXL and paclitaxel (PTX).Methods: A biodegradable and tumor microenvironment (TME)-sensitive mPEG-coated dendritic polylysine material (PDPLL) was synthesized. This material was used to construct single-molecule nanoparticles to co-deliver PTX and siAXL. The drug encapsulation and morphological properties of the nanoparticles (NPs) were characterized. The sensitivity of the NPs to the TME was evaluated in vitro with a dialysis method. The tumor-targeting effect of the PDPLL NPs was evaluated by fluorescence imaging and drug distribution evaluation in vivo. The ability to overcome drug resistance was evaluated using PTX-resistant 4T1 cells (4T1/PTX cells) in both in vitro and in vivo models.Results: PDPLL NPs had a particle size of 49.6 +/- 5.9 nm and a zeta potential of 7.87 +/- 0.68 mV. The PTX drug loading (DL)% was 2.59%. The siAXL DL was 2.5 mg PDPLL: 10 nmol siAXL. The release of PTX showed sustained release performance. The release of siAXL showed sensitivity for the TME. The NPs were stable in the plasma. The NPs promoted cell uptake by PTX-resistant 4T1 cells (4T1/PTX) and promoted tumor targeting and permeability in vivo. siAXL enhanced the toxicity and apoptosis efficiency of PTX in 4T1/PTX cells, as well as the cycle arrest efficiency caused by PTX. The NPs improved the above effects. In mouse 4T1/PTX orthotopic tumors, the NPs enhanced the sensitization of PTX to siAXL.Conclusion: The PDPLL NP co-delivery system possesses good encapsulating potential not only for PTX but also for siRNA. It can enhance the tumor-targeting effect and overcome the drug resistance of 4T1/PTX both in vitro and in vivo. This system is a potential delivery system for RNAs.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Co-delivery of gemcitabine and paclitaxel plus NanoCpG empowers chemoimmunotherapy of postoperative "cold" triple-negative breast cancer
    Guo, Beibei
    Qu, Yan
    Sun, Yinping
    Zhao, Songsong
    Yuan, Jiandong
    Zhang, Peizhuo
    Zhong, Zhiyuan
    Meng, Fenghua
    BIOACTIVE MATERIALS, 2023, 25 : 61 - 72
  • [2] Ratiometric co-delivery of doxorubicin and paclitaxel prodrug by remote-loading liposomes for the treatment of triple-negative breast cancer
    Wang, Yingli
    Chen, Lixue
    Zhang, Zonglin
    Liu, Wenqi
    Li, Lei
    DRUG DELIVERY AND TRANSLATIONAL RESEARCH, 2022, 12 (10) : 2537 - 2549
  • [3] Ratiometric co-delivery of doxorubicin and paclitaxel prodrug by remote-loading liposomes for the treatment of triple-negative breast cancer
    Yingli Wang
    Lixue Chen
    Zonglin Zhang
    Wenqi Liu
    Lei Li
    Drug Delivery and Translational Research, 2022, 12 : 2537 - 2549
  • [4] A Novel Paclitaxel Derivative for Triple-Negative Breast Cancer Chemotherapy
    Liu, Yuetong
    Hong, Ge
    Mao, Lina
    Su, Zhe
    Liu, Tianjun
    Liu, Hong
    MOLECULES, 2023, 28 (09):
  • [5] IRE1α inhibitor enhances paclitaxel sensitivity of triple-negative breast cancer cells
    Wu, Min
    Zhang, Lin
    Pi, Lifu
    Liu, Layang
    Wang, Siyu
    Wu, Yujie
    Pan, Hongli
    Liu, Mingyao
    Yi, Zhengfang
    CELLULAR ONCOLOGY, 2024, 47 (05) : 1797 - 1809
  • [6] Gefitinib enhances response to chemotherapy in triple-negative Breast Cancer (BrCa)
    Corkery, B.
    O'Donovan, N.
    Clynes, M.
    Crown, J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 185 - 185
  • [7] Methylseleninic Acid Enhances Paclitaxel Efficacy for the Treatment of Triple-Negative Breast Cancer
    Qi, Yanfeng
    Fu, Xueqi
    Xiong, Zhenggang
    Zhang, Haitao
    Hill, Steven M.
    Rowan, Brian G.
    Dong, Yan
    PLOS ONE, 2012, 7 (02):
  • [8] Co-delivery of paclitaxel and curcumin by biodegradable polymeric nanoparticles for breast cancer chemotherapy
    Xiong, Kang
    Zhang, Yan
    Wen, Qian
    Luo, Jia
    Lu, Yun
    Wu, ZhouXue
    Wang, BiQiong
    Chen, Yue
    Zhao, Ling
    Fu, ShaoZhi
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2020, 589
  • [9] Co-delivery of IKBKE siRNA and cabazitaxel by hybrid nanocomplex inhibits invasiveness and growth of triple-negative breast cancer
    Zhao, Zhen
    Li, Yuanke
    Liu, Hao
    Jain, Akshay
    Patel, Pratikkumar Vinodchandra
    Cheng, Kun
    SCIENCE ADVANCES, 2020, 6 (29)
  • [10] Co-Delivery of 5-Fluorouracil and Paclitaxel in Mitochondria-Targeted KLA-Modified Liposomes to Improve Triple-Negative Breast Cancer Treatment
    Chen, Tianyu
    Chen, Hui
    Jiang, Yichun
    Yan, Qi
    Zheng, Shuling
    Wu, Min
    PHARMACEUTICALS, 2022, 15 (07)